martes, 5 de noviembre de 2019

Halozyme's lead drug fails; company will cut 55% of workforce

Halozyme's lead drug fails; company will cut 55% of workforce

Cancer Briefing

STAT Plus: Halozyme’s lead drug fails; company will cut 55% of workforce in bid for profitability

By MATTHEW HERPER


ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME
The company will refocus on its drug delivery technology, which is being used by drug giants including Roche, Johnson & Johnson, and Bristol-Myers Squibb.

No hay comentarios: